HGH Side Effects: Carpal Tunnel, Insulin Resistance, Acromegaly & More (2026)

HGH is often presented as a safe, side-effect-free alternative to anabolic steroids. This is inaccurate. While its risk profile differs substantially from anabolic steroids — it does not suppress the HPG axis, does not produce hepatotoxicity, and does not cause cardiovascular lipid disruption — it carries its own unique set of adverse effects, some of which are irreversible at high doses used long-term. This clinical overview examines each adverse effect category with accuracy.

HGH Side Effect Summary Table

Side Effect	Dose Threshold	Incidence	Reversibility
Water retention / oedema	2+ IU/day	Very common	Fully reversible
Carpal tunnel syndrome	3+ IU/day	Common	Reversible with dose reduction
Insulin resistance	4+ IU/day	Very common	Largely reversible post-cycle
Joint pain / arthralgia	Any dose	Common	Reversible
Acromegalic features	6+ IU/day long-term	Uncommon at performance doses	Bone changes irreversible
Gynaecomastia	Any dose with AAS	Uncommon (HGH alone)	May require surgery
Headache	Any dose	Common initially	Usually transient (weeks 1–4)
Potential oncogenic promotion	Any dose	Unknown (theoretical)	N/A — primary contraindication

Water Retention and Peripheral Oedema

The most common early side effect of HGH use. HGH stimulates sodium and water retention through mechanisms including renal tubular reabsorption and increased aldosterone sensitivity. Most users experience pitting oedema in the extremities — particularly in the hands and feet — within the first 2–4 weeks of use. This typically subsides as the body adapts over 4–6 weeks, or with dose reduction. Management: reduce sodium intake, increase potassium-rich foods, reduce dose temporarily. Severe peripheral oedema should prompt dose reduction.

Carpal Tunnel Syndrome

One of the most reliably reported HGH side effects. The underlying mechanism is fluid accumulation in the carpal tunnel, compressing the median nerve. Symptoms include numbness, tingling, and pain in the thumb, index, middle, and ring fingers — typically worse at night. At doses of 4+ IU/day, carpal tunnel symptoms affect a substantial proportion of users. Management: dose reduction is the most effective strategy. Wrist splinting at night provides symptomatic relief. Symptoms fully resolve after cessation or significant dose reduction in virtually all cases.

Insulin Resistance and Glycaemic Effects

HGH is a counter-regulatory hormone to insulin — physiologically, it rises when insulin falls (e.g., fasting, exercise) and suppresses insulin-mediated glucose uptake to prioritise fuel for the brain. At supraphysiological doses, this becomes clinically significant insulin resistance. Fasting blood glucose may rise 0.5–2 mmol/L above baseline at 4 IU/day.

Monitoring: fasting blood glucose before starting HGH, and monthly thereafter. HbA1c at baseline and every 3 months at doses of 4+ IU/day. Targets: fasting glucose <5.6 mmol/L; HbA1c <42 mmol/mol. See our safe use guide for comprehensive blood monitoring protocols. Insulin resistance is largely reversible after cessation but may take several months at high doses.

Joint Pain and Arthralgia

Joint pain — particularly in the knees, hips, and shoulders — is commonly reported, especially during the first few weeks of HGH use. The mechanism is complex: fluid accumulation around joints from water retention, plus the rapid connective tissue remodelling driven by IGF-1 stimulation. Most users find joint pain resolves within 4–6 weeks of consistent use as connective tissue adapts. Some users actually report significant joint improvement over longer cycles as tendon and cartilage integrity improves.

Acromegalic Features: The Most Serious Long-Term Risk

Acromegaly is the clinical syndrome caused by sustained excess GH in adults (after growth plates have closed). Features include progressive enlargement of the jaw, forehead, hands, and feet; coarsening of facial features; thickening of the skin; and internal organ enlargement (cardiomegaly, visceromegaly). In clinical acromegaly (caused by pituitary tumours secreting GH continuously), these changes progress over years and are irreversible once established.

In the context of performance HGH use, most athletes use doses of 2–6 IU/day for 3–6 months at a time, not the continuous years-long exposure of pathological acromegaly. However, users who maintain 6–12 IU/day continuously over years do report subtle facial and skeletal changes consistent with early acromegalic features. Bone changes are irreversible. This represents the most serious potential long-term consequence of chronic high-dose HGH use.

Gynaecomastia

HGH alone rarely causes significant gynaecomastia. However, HGH potentiates IGF-1, which has been shown to sensitise breast tissue to oestrogens. When HGH is combined with aromatising anabolic steroids (testosterone, Dianabol, Deca-Durabolin), the combined IGF-1 + oestrogen stimulus can accelerate gynaecomastia development in predisposed individuals. Aggressive AI use is appropriate in combined HGH + AAS cycles. For context on managing oestrogenic side effects from combined cycles, see our guides on individual compound side effects.

Headache

Headaches are common in the first 2–4 weeks of HGH use, related to the rapid increase in IGF-1 and fluid shifts. They are almost always transient and resolve without intervention. Ensure adequate hydration. If headaches are persistent or severe, dose reduction is warranted.

Oncogenic Promotion: Understanding the Real Risk

IGF-1 is a potent growth factor that has been shown in laboratory settings to promote proliferation of many cancer cell types. This has led to theoretical concern that supraphysiological IGF-1 from HGH use may promote growth of pre-existing but subclinical malignancies. Importantly:

• Evidence in humans is epidemiological and associative, not established causation
• The risk appears most relevant to people with pre-existing malignancy, not healthy athletes
• HGH does not appear to initiate malignancy in clinical evidence
• Active cancer or strong family history of hormone-sensitive cancers (prostate, breast, colorectal) represents an absolute contraindication to HGH use

What HGH Does NOT Cause (Compared to Steroids)

• No hepatotoxicity — HGH is not C-17aa alkylated and does not stress the liver. LFTs remain normal throughout HGH use.
• No HPG axis suppression — HGH does not suppress testosterone, LH, or FSH. PCT is not required after HGH use.
• No lipid profile disruption — HDL and LDL are not negatively affected by HGH; in fact, some studies suggest HGH slightly improves HDL.
• No androgenic side effects — no acne, no hair loss acceleration, no virilisation.

Frequently Asked Questions

Does HGH cause big feet and a big forehead?

At the doses and durations used by most performance athletes (2–6 IU/day for 3–6 months per year), clinically significant acromegalic changes are unlikely. The risk increases substantially with sustained high doses (6+ IU/day) maintained continuously for multiple years. This is the pattern of use seen in elite bodybuilders who develop visible facial changes — not the profile of most recreational HGH users.

Is carpal tunnel permanent?

No. Carpal tunnel from HGH is caused by fluid accumulation — it is fully reversible with dose reduction or cessation. This differentiates it from true carpal tunnel syndrome caused by repetitive mechanical injury, which may require surgical intervention.

Can HGH cause diabetes?

Long-term high-dose HGH can potentially unmask latent type 2 diabetes in predisposed individuals by driving sustained insulin resistance. In people without underlying metabolic risk, insulin resistance from performance-dose HGH (2–6 IU/day) is typically fully reversible. Blood glucose monitoring is essential throughout use.